Carmat resumed the EU pivotal trial of its artificial heart after addressing regulator concerns. We anticipate that the study could be completed in mid-2019, leading to a potential EU launch in 2020. The Carmat device could potentially fill a significant need among those waiting for human transplants and/or with terminal heart failure (HF) or acute myocardial infarction (MI). Our valuation is €627m, down from €747m previously.
31 Jul 2017
Back on track as pivotal study resumes
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Back on track as pivotal study resumes
Carmat SA (ALCAR:PAR) | 0 0 0.7% | Mkt Cap: 195.7m
- Published:
31 Jul 2017 -
Author:
Pooya Hemami -
Pages:
16
Carmat resumed the EU pivotal trial of its artificial heart after addressing regulator concerns. We anticipate that the study could be completed in mid-2019, leading to a potential EU launch in 2020. The Carmat device could potentially fill a significant need among those waiting for human transplants and/or with terminal heart failure (HF) or acute myocardial infarction (MI). Our valuation is €627m, down from €747m previously.